Thromboembolic Pulmonary Hypertension
📧 Sign up to get email alerts when something new happens for Thromboembolic Pulmonary Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-11-30FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for ADEMPAS (riociguat) filed by Bayer HealthCare Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2020-10-22Clinical Trial Update: BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension [Phase 3]
Long-term extension Phase 3 trial for BAY63-2521 in chronic thromboembolic pulmonary hypertension has completed with results posted in 2020.
-
FDA approval · 2020-02-10FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for ADEMPAS (riociguat) submitted by Bayer HealthCare Pharmaceuticals Inc.
-
CLINICAL_TRIALS research · 2019-12-24Clinical Trial Update: RF Surgical Sponge-Detecting System on the Function of Pacemakers and Implantable Cardioverter Defibrillators [NA]
A completed clinical trial evaluating a sponge-detecting system used during surgery to assess its impact on pacemaker and ICD function.
-
CLINICAL_TRIALS trial_result · 2019-06-10Clinical Trial Update: Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH) [Phase 3]
Phase 3 trial assessing efficacy and tolerability of subcutaneously administered treprostinil sodium in patients with severe non-operable ch…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2019-02-12Clinical Trial Update: Iodine Subtraction Mapping in the Diagnosis of Chronic Pulmonary Thromboembolic Disease
This clinical trial evaluates iodine subtraction mapping as a diagnostic approach for Chronic Thromboembolic Pulmonary Hypertension, with th…
-
FDA approval · 2018-12-06FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for ADEMPAS (riociguat) filed by Bayer HealthCare Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2018-08-29Clinical Trial Update: Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH [Phase 2]
Phase 2 pilot study assessing the effect of riociguat on right ventricular function in chronic thromboembolic pulmonary hypertension has bee…
-
CLINICAL_TRIALS research · 2018-03-02Clinical Trial Update: Lung Perfusion Measured With Dual-Energy CT in Patients With Chronic Thromboembolic Pulmonary Hypertension: Comparative Study With Right Heart Catheterization and V/Q
A clinical trial update evaluating lung perfusion using dual-energy CT in patients with chronic thromboembolic pulmonary hypertension. It co…
-
CLINICAL_TRIALS trial_result · 2018-01-23Clinical Trial Update: Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension [Phase 2]
Phase 2 study evaluating the efficacy, safety and tolerability of macitentan in inoperable chronic thromboembolic pulmonary hypertension has…
-
FDA approval · 2018-01-11FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approves a supplemental application for ADEMPAS (riociguat) submitted by Bayer HealthCare Pharmaceuticals Inc.
-
CLINICAL_TRIALS research · 2017-11-21Clinical Trial Update: Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region
This item reports an update to a registry of patients with chronic thromboembolic pulmonary hypertension in the Novosibirsk region, sponsore…
-
CLINICAL_TRIALS trial_result · 2017-07-07Clinical Trial Update: NIMS- New Implantable Pump in Pulmonary Arterial Hypertension, a Safety Follow up
A completed clinical trial update on the NIMS implantable pump for pulmonary arterial hypertension, focusing on safety follow-up.
-
CLINICAL_TRIALS research · 2017-06-09Clinical Trial Update: Registry for Pulmonary Hypertension in China
An update on the Registry for Pulmonary Hypertension in China; the trial status is currently UNKNOWN.
-
CLINICAL_TRIALS trial_result · 2017-06-08Clinical Trial Update: A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) [Phase 3]
Phase 3 open-label study on long-term safety, tolerability, and efficacy of ambrisentan in inoperable chronic thromboembolic pulmonary hyper…
-
CLINICAL_TRIALS trial_result · 2017-05-24Clinical Trial Update: A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
This completed study evaluated real-world treatment patterns in patients with pulmonary arterial hypertension or chronic thromboembolic pulm…
-
CLINICAL_TRIALS trial_result · 2017-05-05Clinical Trial Update: Effect of Long-term Oxygen Therapy on Exercise Capacity and Quality of Life in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension [Phase 3]
Phase 3 clinical trial assessing how long-term oxygen therapy affects exercise capacity and quality of life in patients with pulmonary arter…
-
CLINICAL_TRIALS trial_result · 2017-03-23Clinical Trial Update: Pulmonary Perfusion Heterogeneity in Patients With CTEPH Using Functional PET Imaging
This clinical trial update reports on a completed study evaluating pulmonary perfusion heterogeneity in patients with chronic thromboembolic…
-
FDA approval · 2017-02-23FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for ADEMPAS (riociguat) from Bayer HealthCare Pharmaceuticals Inc.
-
CLINICAL_TRIALS research · 2017-02-16Clinical Trial Update: Long Term Outcomes of Venous Thromboembolism
An update on the long-term outcomes of venous thromboembolism, including post-thrombotic syndrome and chronic thromboembolic pulmonary hyper…
-
FDA approval · 2017-01-17FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for ADEMPAS (riociguat) from Bayer HealthCare Pharmaceuticals Inc., approving a change to the drug's…
-
FDA approval · 2016-10-04FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for ADEMPAS (riociguat) submitted by Bayer HealthCare Pharmaceuticals Inc., resulting in an updated …
-
CLINICAL_TRIALS trial_result · 2016-08-12Clinical Trial Update: Effect of Short-term Oxygen During CPET in Pulmonary Hypertension [Phase 2]
A Phase 2 trial evaluating the effect of short-term oxygen during CPET in pulmonary hypertension has completed.
-
CLINICAL_TRIALS research · 2016-06-06Clinical Trial Update: CTEPH DIAGNOSIS Europe - MRI [Phase 3]
This is an update on a Phase 3 MRI diagnostic trial for chronic thromboembolic pulmonary hypertension in Europe. The sponsor is Hannover Med…
-
CLINICAL_TRIALS other · 2016-06-03Clinical Trial Update: Interventional Treatment of Residual Pulmonary Hypertension in Patients After Pulmonary Thromboendarterectomy [Phase 2]
Phase 2 interventional trial update for residual pulmonary hypertension after pulmonary thromboendarterectomy; trial status is UNKNOWN.